Artra is a model of combination symptom-modifying therapy for osteoarthrosis and intervertebral osteochondrosis
Abstract
The paper gives an update on therapy for osteoarthrosis (OA). Symptomatic sustained-release drugs, particularly structural analogues of the cartilage (glucosamine and chondroitin sulfate), that have the weightiest body of evidence is noted to occupy a special place in the treatment of OA. Therapy involving these agents contributes not only to the suppression of pain and the recovery of affected joint function, but also to the slow progression, normalization, or stabilization of structural changes in the hyaline cartilage, to the prevention of changes in the intact joint, and to improved quality of life in the patients.
References
1. <div><p>Reginster J.Y., Bruyere O., Neuprez A. Роль глюкозамина в терапии остеоартроза. Rheumatology 2010;1:18—25.</p><p>Sellam J., Herrero-Beamont G., Berenbaum F. Osteoarthrosis: pathogenesis, clinical aspects and diagnosis. EULAR. Compendium on Rheumatic Diseases. BMJ 2009;444—64.</p><p>Bateman J.F. Genetic aspects of osteoarthritis. Sem Arthr Rheum 2005;34(Suppl. 2):15—8.</p><p>Smith R.L. Mechanical loading effects on articular cartilage matrix metabolism and osteoarthritis. In: Osteoarthritis, inflammation and degradation: a continuum. IOS Press, 2007;14—30.</p><p>Setnikar I., Cereda R., Pacine M.A. Antireactive properties of glucosamine sulfate. Arzneimittelforschung 1991;41:778—99.</p><p>Altman R.D., Abramson S., Bryere O. et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthr Cart 2006;14:963—6.</p><p>Towheed T.E., Maxwell L., Anastassiades T.P. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2006(4): Accession Number 0075320-1000000000-01942.</p><p>Rovati L.C. Clinical development of glucosamine sulfate in osteoarthritis of the spine. Rev Esp Rheum 1993;20(Suppl. 1):321.</p><p>Reginster J.Y., Deroisy R., Rovati L.C. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251—6.</p><p>Pavelka K., Gatterova J., Olejarova M. et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. ЛИТЕРАТУРА Arch Int Med 2002;162(18):2113—23.</p><p>Bruyere O., Pavelka K., Rovati L.C. et al. Total joint replacement after glucosamine sulphate treatment in knee ostheoarthritis : results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthr Cart 2008;16(2):254—60.</p><p>Henrotin Y. Advances in the treatment of osteoarthritis and role of chondroitin sulphate — a review. Eur Muscul Rev 2010;5(2):11—7.</p><p>Volpi N. Chondroitin sulphate for the treatment of osteoarthritis. Curr Med Chem 2005;4:221—34.</p><p>Jordan K.M., Arden N.K., Doherty M. et al. ЕULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145—55.</p><p>Du Souich P. Immunomodulatory and antiinflammatory effects of chondroitin sulphate. European Musculoskeletal Review 2009;4(2):8—10.</p><p>Leeb B.F., Schweitzer H., Montag K. et al. A Metaanalysis of Chondroitin Sulphate in the Treatment of Osteoarthritis. J Rheum 2000;27:205—11.</p><p>Uebelhart D., Malaise V., Marcolongo R. et al. Intermittent treatment of knee osteoarthritis with oral chondriitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cart 2004;12:269—76.</p><p>Kahan A., Uebelhart D., De Vathaire F. Long-term effects of chondroitins 4 and 6 sul fate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthr Rheum 2009;60(2):524—33.</p><p>Orth M.W., Peters T.L., Hawkins J.N. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Department of Animal Science, Michigan State University, USA 2002.</p><p>Lippielo L., Woodword J., Karpman D. et al. Beneficial effect of cartilage structure modyifing agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999;(Suppl. 42):256.</p><p>Richy F., Bruyere O., Ethgen O. et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. Arch Int Med 2003;163:1514—22.</p><p>Алексеева Л.И., Чичасова Н.В., Беневоленская Л.И. и др. Комбинированный препарат «Артра» в лечении остеоартроза. Тер арх 2005;11:69—75.</p><p>Результаты открытого рандомизированного многоцентрового исследования препарата Артра в России. М.: Unipharm, 2005;11 с.</p><p>Наумов А.В., Верткин А.Л., Мендель О.И. и др. Как повысить безопасность и эффективность «антиартрозной» терапии у пациентов с соматической патологией. МРЖ 2007;15(6):1—8.</p><p>Kwan Tat S., Pelletier J.P., Verges J. et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthr Res Ther 2007;9(6):R117.</p></div><br />
Review
For citations:
Badokin V.V. Artra is a model of combination symptom-modifying therapy for osteoarthrosis and intervertebral osteochondrosis. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):91-96. (In Russ.) https://doi.org/10.14412/2074-2711-2012-392
Views: 709
Email this article 